While co-targeting cdk2 and cdk4/6 with endocrine therapy is promising in the pre-clinical setting, most of these approaches are associated with continued tumor proliferation and tumor relapse, and in most cases, failure to respond to treatment can be fatal. The gene discussed is CDK4; the disease is neoplasm.